相关实验视频
Updated: Aug 14, 2026

07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
阿尔茨海默氏症粉样蛋白前体复合物与大脑GTP结合蛋白G (o)
I Nishimoto1, T Okamoto, Y Matsuura
1Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Japan.
Nature
|March 4, 1993
概括
阿尔茨海默病涉及粉样前体蛋白 (APP) 的变化. 这项研究揭示了APP作为受体,与G(o) 蛋白形成复合体,表明异常的APP-G(o) 信号有助于阿尔茨海默病的发病.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病的特点是粉样β/A4蛋白沉积物,来自其前体蛋白 (APP).
- 在APP的结构变化与阿尔茨海默氏症的发病有关,但潜在的机制仍然不清楚.
- APP具有类似受体的结构,但其特定的受体功能以前没有被证明.
研究的目的:
- 为了研究APP的潜在受体功能.
- 为了确定APP是否与大脑中已知的信号蛋白相互作用.
- 阐明APP蛋白相互作用在阿尔茨海默病中的作用.
主要方法:
- 研究了脑组织中APP和GTP结合蛋白之间的相互作用.
- 确定了负责蛋白质复合体形成的特定APP序列.
- 评估了GTP-gamma S对APP-G) 蛋白相互作用的影响.
主要成果:
- 粉样蛋白前体蛋白 (APP) 与GTP结合蛋白G (o) 形成复合体.
- 一个特定的细胞质序列APP (His 657-Lys 676) 介导G(o) 结合和激活.
- 当 GTP-gamma S 与 GTP-gamma S 结合时,它失去了与 APP 结合的能力.
结论:
- APP 作为与 G ((o) 蛋白结合的受体起作用.
- 异常的APP-G信号与阿尔茨海默病的病理过程有关.
- 这一发现为阿尔茨海默病的发病机制提供了新的分子机制.
相关概念视频
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

